SAN FRANCISCO and BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 2:00 p.m. E.T. A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Apogee Therapeutics website. About ApogeeApogee Therapeutics is a clinical-stage biotechnology comp ...

Apogee Therapeutics has a strong financial health with a cash reserve of $913 million, supporting operations until 2028.Citigroup maintains a "Buy" rating for Apogee Therapeutics, highlighting confidence in the company's future.Apogee's drug, Zumilokibart, shows promise with an extended half-life and a clean safety profile, potentially enhancing its market position.Apogee Therapeutics (NASDAQ:APGE) is a company focused on advancing treatments in the field of immunology. It is working on optimizing the IL-13 ...

Apogee Therapeutics ( APGE ) is at an important crossroads that I believe creates a reasonable, yet risk weighted opportunity for investors seeking exposure to the next generation of biologic products. My thesis for Apogee is based onI have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and investing in disruptive technologies and forward-thinking enterprises. My approach is a mix of fundamental analysis and ...

Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing next-generation biologics for immunological and inflammatory disorders, particularly targeting atopic dermatitis and COPD [5] - The company aims to deliver differentiated, long-acting therapies through proprietary antibody engineering, establishing a competitive position in the specialty therapeutics market [5] Recent Transaction Details - Carl Dambkowski, the chief medical officer at Apogee Therapeutics, executed an open-market sale of 18,700 shares for a total transaction value of $1.46 million, following the exercise of 14,025 stock options [4] - The weighted average sale price was approximately $77.84 per share, closely matching the market close of $78.95 on that date, indicating execution near the prevailing price level [1] Equity Exposure and Transaction Structure - After the transaction, Dambkowski retains 212,523 directly held shares, valued at about $16.8 million [2][6] - The transaction was executed under a Rule 10b5-1 trading plan and followed the exercise of vested options, reflecting a structured liquidity event rather than a signal of clinical confidence [6] Comparison with Previous Transactions - The sale of 18,700 shares is significantly larger than Dambkowski's recent median sell size of 3,690 shares and also exceeds the earlier median sell size of 6,665 shares, highlighting the impact of the option exercise on transaction scale [3] Company Performance and Market Position - Apogee Therapeutics shares have increased approximately 60% over the past year, outperforming the S&P 500's roughly 18% gain, driven by growing confidence in its immunology pipeline and balance sheet strength [7] - The company closed the third quarter with $913 million in pro forma cash, cash equivalents, and marketable securities, providing financial runway into the second half of 2028 [7] - Positive interim Phase 1b data for zumilokibart in asthma has been reported, showing durable biomarker suppression and supporting less frequent dosing, with multiple Phase 2 readouts scheduled for 2026 [7]

Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing next-generation biologic therapies for inflammatory and immunological diseases, leveraging proprietary antibody technology to address significant unmet needs in dermatology and pulmonology [6]. Recent Transaction - Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, executed an open-market sale of 10,900 shares for approximately $817,500 on December 4, 2025, marking the largest single open-market transaction by Dambkowski in the past 12 months [4]. - Dambkowski's direct holdings have decreased from 331,948 shares at the start of 2025 to 271,108 shares after this transaction, reflecting an 18.33% reduction [2]. Impact of the Transaction - The sale accounted for 3.87% of Dambkowski's direct holdings, which is significantly higher than the median per-sale impact of 1.13% over the past year, indicating a notable increase in share disposition [3]. - The transaction was part of a Rule 10b5-1 trading plan, allowing insiders to sell shares at prearranged intervals, which helps mitigate insider trading risks [7]. Clinical Developments - Apogee recently reported positive results from a clinical trial of zumilokibart (APG777) in patients with mild to moderate asthma, showing robust and durable suppression of FeNO, a biomarker of Type 2 inflammation [8]. - Anticipated milestones for 2026 include further developments for zumilokibart and a treatment for atopic dermatitis [8]. Market Context - The biotechnology sector is characterized by high-risk and high-reward dynamics, with significant investment required for research and development of medical therapies [9]. - Apogee appears to be gaining momentum as it approaches 2026, particularly following a substantial stock price increase of over 45% in December 2025 [7].

Core Viewpoint - The article summarizes significant analyst rating changes that could impact market trends, highlighting upgrades, downgrades, and new coverage ratings for various companies [1][6]. Upgrades - Barclays upgraded Whirlpool (W) from "Neutral" to "Overweight," raising the target price from $104 to $123, citing accelerated market share growth expected in 2025 and continuation into 2026 [5]. - Oppenheimer upgraded McDonald's (MCD) from "Market Perform" to "Outperform," setting a target price of $355, with a more optimistic outlook for the restaurant sector in 2026 despite a poor performance in 2025 [5]. - Barclays upgraded Lowe's (LOW) from "Neutral" to "Overweight," increasing the target price from $259 to $285, based on an expected improvement in non-essential goods demand due to upcoming tax policy changes [5]. - Piper Sandler upgraded Hershey (HSY) from "Neutral" to "Overweight," raising the target price from $193 to $213, noting lower cocoa costs and the removal of cocoa tariffs, which provide flexibility for reinvestment and growth [5]. - Bank of America upgraded Regeneron Pharmaceuticals (REGN) from "Underperform" to "Buy," significantly raising the target price from $627 to $860, as previous concerns regarding Eylea SD have been addressed [5]. Downgrades - Jefferies downgraded First Solar (FSLR) from "Buy" to "Hold," lowering the target price from $269 to $260 due to limited visibility on orders and emerging strategic issues [10]. - Oppenheimer downgraded Yum Brands (YUM) from "Outperform" to "Market Perform," with no target price set, as the stock's risk-reward profile has become balanced after a 13% increase in 2025 [10]. - Montreal Bank Capital Markets downgraded Union Pacific Railroad (UNP) from "Outperform" to "Market Perform," reducing the target price from $270 to $255, citing high uncertainty regarding regulatory outcomes and weak freight demand [10]. - Piper Sandler downgraded Deckers Outdoor (DECK) from "Neutral" to "Underweight," lowering the target price from $100 to $85, as the company has increased discount promotions on its core brands [10]. - Wells Fargo downgraded Humana (HUM) from "Overweight" to "Neutral," setting a target price of $290, due to uncertainties regarding profit margin targets for 2026 [10]. New Coverage - Argus Research initiated coverage on grocery delivery platform Instacart (CART) with a "Buy" rating and a target price of $52, highlighting revenue growth and recent profitability achievements [11]. - Citigroup initiated coverage on Natera (NTRA) with a "Buy" rating and a target price of $300, citing significant growth potential [11]. - Link Consulting initiated coverage on Galecto (GLTO) with an "Outperform" rating and a target price of $46, noting its acquisition of Damola Therapeutics to advance its oncology pipeline [11]. - Wolfe Research initiated coverage on Apogee Therapeutics (APGE) with a "Market Perform" rating, without a target price, predicting mixed catalysts for the stock in 2026 [11]. - Mizuho Securities initiated coverage on Palvella Therapeutics (PVLA) with an "Outperform" rating and a target price of $205, based on positive clinical trial data for its drug Qtorin [11].

Core Insights - The conference call is hosted by Apogee Therapeutics, focusing on the company's latest developments and clinical programs [1][2] - The lead program discussed is zumilokibart (APG777), aimed at addressing asthma treatment [3] Company Developments - CEO Michael Henderson will introduce Apogee's latest developments and the goal of delivering a robust pipeline [3] - The call will include a presentation of Phase Ib interim results for zumilokibart in patients with mild to moderate asthma by Chief Medical Officer Carl Dambkowski [3]

Apogee Therapeutics (NasdaqGM:APGE) Update / Briefing January 06, 2026 08:00 AM ET Company ParticipantsDavid Nierengarten - Managing Director of Equity ResearchMichael Henderson - CEOMario Castro - Chief of Pulmonary Critical Care and Sleep Medicine DivisionNoel Kurdi - VP of Investor RelationsCarl Dambkowski - Chief Medical OfficerJeff Hartness - Chief Commercial OfficerAlex Thompson - Managing Director of BiotechnologyPhoebe Tan - Senior Biotechnology Equity Research AssociateDavid Huang - VP of Equity Re ...

Title text 2 Zumilokibart (APG777) Asthma Phase 1b Interim Results January 6, 2026 Disclaimers and Forward-looking Statements This presentation contains certain "forward-looking statements" within the meaning of applicable securities laws. Other than statements of historical facts, all statements included in this presentation are forward-looking statements, including statements about the potential for zumilokibart (APG777) in asthma; Apogee's plans for its current and future product candidates and programs; ...

Core Insights - Apogee Therapeutics announced positive interim results from the Phase 1b trial of zumilokibart (APG777) in patients with mild-to-moderate asthma, demonstrating rapid and durable suppression of FeNO, a key biomarker of Type 2 inflammation [3][5][6] - The company aims to advance zumilokibart in asthma and atopic dermatitis, with significant milestones expected in 2026, including the initiation of Phase 3 trials [4][8] Phase 1b Trial Results - The Phase 1b trial involved 19 adult patients with mild-to-moderate asthma, showing a maximum absolute mean FeNO reduction of 45 ppb, representing a 60% decrease from baseline after a single dose of 720 mg of zumilokibart [5][6] - The treatment exhibited a favorable safety profile, with no serious adverse events reported and only two patients experiencing gastroesophageal reflux disease [6][7] Future Development Plans - Zumilokibart is advancing in Phase 2 APEX trials for atopic dermatitis, with Part A maintenance data readout expected in Q1 2026 and Part B induction data readout on track for Q2 2026 [8][10] - The company has a strong cash position of $913 million, providing a runway into the second half of 2028, supporting the potential launch of zumilokibart in 2029 [8][10] Market Potential - Apogee aims to establish a best-in-class profile for zumilokibart in the atopic dermatitis market, projected to exceed $50 billion, while also expanding its indications for other inflammatory and immunology diseases [8][10] - The company is focused on serial innovation in atopic dermatitis and plans to report multiple clinical data readouts in 2026, setting the stage for potential Phase 3 trial initiation [4][8]